Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones.
Breast Neoplasms
/ genetics
Cell Communication
/ genetics
Cell Line, Tumor
Cell Transformation, Neoplastic
/ genetics
Class I Phosphatidylinositol 3-Kinases
/ genetics
Coculture Techniques
Female
Fibronectins
/ antagonists & inhibitors
Gene Expression Regulation, Neoplastic
Gene Frequency
Gene Knockout Techniques
Humans
Immunohistochemistry
MCF-7 Cells
Mutation
Phenotype
Receptor, ErbB-2
/ genetics
Breast cancer
Cell Biology
Molecular biology
Molecular genetics
Oncology
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
15 03 2021
15 03 2021
Historique:
received:
24
08
2020
accepted:
27
01
2021
pubmed:
3
2
2021
medline:
30
9
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
Intratumor heterogeneity is an important mediator of poor outcomes in many cancers, including breast cancer. Genetic subclones frequently contribute to this heterogeneity; however, their growth dynamics and interactions remain poorly understood. PIK3CA and HER2 alterations are known to coexist in breast and other cancers. Herein, we present data that describe the ability of oncogenic PIK3CA mutant cells to induce the proliferation of quiescent HER2 mutant cells through a cell contact-mediated mechanism. Interestingly, the HER2 cells proliferated to become the major subclone over PIK3CA counterparts both in vitro and in vivo. Furthermore, this phenotype was observed in both hormone receptor-positive and -negative cell lines, and was dependent on the expression of fibronectin from mutant PIK3CA cells. Analysis of human tumors demonstrated similar HER2:PIK3CA clonal dynamics and fibronectin expression. Our study provides insight into nonrandom subclonal architecture of heterogenous tumors, which may aid the understanding of tumor evolution and inform future strategies for personalized medicine.
Identifiants
pubmed: 33529175
pii: 143557
doi: 10.1172/JCI143557
pmc: PMC7954606
doi:
pii:
Substances chimiques
FN1 protein, human
0
Fibronectins
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : R01 CA194024
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA211695
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA098131
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007347
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214494
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA068485
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009592
Pays : United States
Références
Nature. 2020 Feb;578(7793):122-128
pubmed: 32025013
Mol Biol Cell. 1995 Mar;6(3):273-82
pubmed: 7612963
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Methods. 2003 Jul;30(3):256-68
pubmed: 12798140
J Biol Chem. 1994 Oct 28;269(43):26602-5
pubmed: 7929388
Mol Cell Proteomics. 2015 Jul;14(7):1959-76
pubmed: 25953087
J Clin Invest. 2019 Aug 8;129(11):4708-4723
pubmed: 31393856
Nat Med. 2015 Jul;21(7):751-9
pubmed: 26099045
Clin Cancer Res. 2013 Oct 1;19(19):5413-22
pubmed: 23888070
Endocrinology. 2001 Jul;142(7):3214-22
pubmed: 11416044
Nature. 2010 Jan 28;463(7280):545-8
pubmed: 20072127
Cancer. 2004 Mar 15;100(6):1110-22
pubmed: 15022276
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Biochem J. 1997 Aug 15;326 ( Pt 1):61-8
pubmed: 9337851
Nature. 2014 Oct 2;514(7520):54-8
pubmed: 25079331
J Biol Chem. 1996 Aug 23;271(34):20608-16
pubmed: 8702807
Oncogene. 2010 Apr 22;29(16):2337-45
pubmed: 20101210
Int J Oncol. 2005 Oct;27(4):1005-11
pubmed: 16142317
Biophys J. 2003 Feb;84(2 Pt 1):1252-62
pubmed: 12547805
Genes Dev. 2010 Aug 15;24(16):1731-45
pubmed: 20713517
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Breast Cancer (Dove Med Press). 2015 May 15;7:111-23
pubmed: 26028978
FASEB J. 2016 Oct;30(10):3441-3452
pubmed: 27383183
Endocrinology. 1999 Aug;140(8):3615-22
pubmed: 10433219
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13474-9
pubmed: 16938860
J Natl Cancer Inst. 1973 Nov;51(5):1409-16
pubmed: 4357757
Cancer Res. 1990 Sep 15;50(18):6075-86
pubmed: 1975513
Cancer Cell. 2014 Mar 17;25(3):282-303
pubmed: 24651011
Nat Biotechnol. 2020 Jan;38(1):97-107
pubmed: 31919445
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Genet. 2015 Oct;47(10):1212-9
pubmed: 26301495
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6205-14
pubmed: 26508629
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2835-40
pubmed: 19196980
Cancer Discov. 2015 May;5(5):520-33
pubmed: 25735774
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Cancer Cell. 2011 Feb 15;19(2):244-56
pubmed: 21316603
Sci Transl Med. 2017 Aug 9;9(402):
pubmed: 28794284
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nature. 2014 Apr 3;508(7494):113-7
pubmed: 24695311
Nature. 1984 May 3-9;309(5963):30-3
pubmed: 6325925
Respir Res. 2009 Mar 09;10:18
pubmed: 19272161